Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally.
The company’s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2014 |
| IPO Date | Jun 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 650 |
| CEO | Christian Itin |
Contact Details
Address: The Mediaworks, 191 Wood Lane London, W12 7FP United Kingdom | |
| Phone | 44 20 3829 6230 |
| Website | autolus.com |
Stock Details
| Ticker Symbol | AUTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730463 |
| CUSIP Number | 05280R100 |
| ISIN Number | US05280R1005 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer and Director |
| Alex Driggs | Senior Vice President of Legal Affairs and General Counsel and Secretary |
| Dr. Christopher Williams | Chief Business Officer |
| Dr. Matthias Will M.D. | Senior Vice President and Chief Development Officer |
| Dr. Martin Pule M.D., MBBS | Founder, Senior Vice President and Chief Scientific Officer |
| Robert F. Dolski | Senior Vice President and Chief Financial Officer |
| Christopher Vann | Senior Vice President and Chief Operating Officer |
| Patrick McIlvenny | Senior Vice President of Finance and Chief Accounting Officer |
| Miranda Neville | Chief Technology Officer |
| Olivia Manser | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2025 | SCHEDULE 13G/A | Filing |
| Dec 2, 2025 | 424B3 | Prospectus |
| Dec 2, 2025 | 8-K | Current Report |
| Nov 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 14, 2025 | SCHEDULE 13G | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 424B3 | Prospectus |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |
| Oct 6, 2025 | SCHEDULE 13G/A | Filing |